Drug Profile


Alternative Names: NSC 640067; NSC 658586

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator National Cancer Institute (USA); Purdue University; University of Missouri-Kansas City
  • Developer National Cancer Institute (USA); University of Missouri-Kansas City
  • Class Antiretrovirals; Cholestanes
  • Mechanism of Action HIV envelope protein gp120 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 13 May 2003 A preclinical study has been added to the Viral Infections pharmacodynamics section
  • 09 Jun 2000 A preclinical study has been added to the pharmacokinetics section
  • 17 Mar 1998 A preclinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top